Envista (NYSE:NVST) Downgraded to Buy Rating by Wall Street Zen

Wall Street Zen lowered shares of Envista (NYSE:NVST) from a strong-buy rating to a buy rating in a research report report published on Saturday.

Several other research analysts have also commented on the stock. Piper Sandler reaffirmed a “neutral” rating and set a $25.00 price objective (up from $21.00) on shares of Envista in a research note on Friday, February 6th. Wells Fargo & Company lifted their price objective on shares of Envista from $21.00 to $26.00 and gave the stock an “equal weight” rating in a research note on Friday, February 6th. Mizuho lifted their price objective on shares of Envista from $24.00 to $27.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 10th. Evercore reaffirmed an “outperform” rating and set a $33.00 price objective on shares of Envista in a research note on Thursday. Finally, Weiss Ratings raised shares of Envista from a “sell (d)” rating to a “hold (c-)” rating in a research note on Tuesday, February 17th. Six research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $28.83.

Envista Stock Down 0.1%

NYSE NVST opened at $24.27 on Friday. The company has a quick ratio of 2.04, a current ratio of 2.44 and a debt-to-equity ratio of 0.47. The company has a fifty day moving average of $26.53 and a two-hundred day moving average of $24.06. The firm has a market capitalization of $3.95 billion, a price-to-earnings ratio of 59.18, a PEG ratio of 1.64 and a beta of 0.92. Envista has a 52 week low of $16.41 and a 52 week high of $30.42.

Envista (NYSE:NVST) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.36 EPS for the quarter, topping the consensus estimate of $0.31 by $0.05. The company had revenue of $705.50 million during the quarter, compared to analyst estimates of $680.04 million. Envista had a net margin of 2.41% and a return on equity of 7.11%. Envista’s quarterly revenue was up 14.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.24 earnings per share. Envista has set its FY 2026 guidance at 1.350-1.450 EPS. On average, analysts predict that Envista will post 1.43 earnings per share for the current year.

Insiders Place Their Bets

In other Envista news, SVP Mischa Reis sold 9,675 shares of the company’s stock in a transaction on Tuesday, February 10th. The stock was sold at an average price of $30.00, for a total value of $290,250.00. Following the completion of the sale, the senior vice president directly owned 32,382 shares in the company, valued at approximately $971,460. This represents a 23.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.99% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Envista

Several hedge funds have recently made changes to their positions in the company. Millennium Management LLC raised its holdings in shares of Envista by 1,442.7% in the fourth quarter. Millennium Management LLC now owns 2,420,615 shares of the company’s stock valued at $52,552,000 after acquiring an additional 2,263,712 shares in the last quarter. Holocene Advisors LP bought a new stake in shares of Envista in the second quarter valued at about $43,936,000. Norges Bank bought a new stake in shares of Envista in the fourth quarter valued at about $45,113,000. Alliancebernstein L.P. raised its holdings in shares of Envista by 34.0% in the second quarter. Alliancebernstein L.P. now owns 6,098,445 shares of the company’s stock valued at $119,164,000 after acquiring an additional 1,547,656 shares in the last quarter. Finally, Freestone Grove Partners LP bought a new stake in shares of Envista in the fourth quarter valued at about $29,046,000.

More Envista News

Here are the key news stories impacting Envista this week:

• Positive Sentiment: Envista reported better-than-expected Q1 2026 results, with EPS of $0.36 versus the $0.31 consensus and revenue of $705.5 million versus $680.0 million expected, suggesting solid demand and execution. Envista (NYSE:NVST) Posts Better-Than-Expected Sales In Q1 CY2026
• Positive Sentiment: Management’s earnings transcript and presentation are likely reinforcing confidence in the turnaround and highlighting new growth drivers, which can support the stock if investors see improving fundamentals. Envista (NVST) Q1 2026 Earnings Transcript
• Positive Sentiment: Robert W. Baird raised its price target on Envista to $31 from $30 and kept an outperform rating, while JPMorgan lifted its target to $29 from $26, signaling improved analyst sentiment after the earnings beat.
• Positive Sentiment: Zacks highlighted Envista as a top long-term growth stock, which may help reinforce the market’s view that the company has attractive longer-term earnings potential. Why Envista (NVST) is a Top Growth Stock for the Long-Term
• Neutral Sentiment: Additional coverage on the Q1 earnings snapshot and key metrics is mostly informational, but it keeps the company in focus as investors assess whether the earnings beat is sustainable. Envista: Q1 Earnings Snapshot
• Neutral Sentiment: The stock still faces some caution because JPMorgan’s rating remained neutral despite the higher target, indicating analysts see upside but not a clear near-term rerating.

About Envista

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.